{"organizations": [], "uuid": "aa2c0912e2751561b31cbf74a30a0278628632c1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180410.html", "section_title": "Archive News &amp; Video for Tuesday, 10 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-advicenne-fy-operating-loss-widens/brief-advicenne-fy-operating-loss-widens-to-6-0-million-euros-idUSW8N1KI00L", "country": "US", "domain_rank": 408, "title": "BRIEF-Advicenne FY Operating Loss Widens To 6.0 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.874, "site_type": "news", "published": "2018-04-11T00:18:00.000+03:00", "replies_count": 0, "uuid": "aa2c0912e2751561b31cbf74a30a0278628632c1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-advicenne-fy-operating-loss-widens/brief-advicenne-fy-operating-loss-widens-to-6-0-million-euros-idUSW8N1KI00L", "ord_in_thread": 0, "title": "BRIEF-Advicenne FY Operating Loss Widens To 6.0 Million Euros", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "cystinuria", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10 (Reuters) - ADVICENNE SA:\n* FY REVENUE EUR 0.6 MILLION VERSUS EUR 0.3 MILLION YEAR AGO\n* FY OPERATING LOSS EUR 6.0 MILLION VERSUS LOSS EUR 3.2 MILLION YEAR AGO\n* FY NET LOSS EUR 6.0 MILLION VERSUS LOSS EUR 3.6 MILLION YEAR AGO\n* PLANS TO LAUNCH TWO PIVOTAL STUDIES WITH ADV7103 IN 2018 * ADV7103: PLANS TO LAUNCH IN H2 PHASE II/III PIVOTAL CLINICAL TRIAL IN US IN DRTA PATIENTS\n* ADV7103: PLANS TO LAUNCH IN H1 PHASE II/III PIVOTAL CLINICAL TRIAL IN EUROPE IN CYSTINURIA PATIENTS\n* CASH AND CASH EQUIVALENTS AT END-DEC. EUR 36.2 MILLION Source text : bit.ly/2HqTIoD Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://bit.ly/2HqTIoD", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://instagram.com/reuters/"], "published": "2018-04-11T00:18:00.000+03:00", "crawled": "2018-04-11T18:23:37.000+03:00", "highlightTitle": ""}